Teleflex (($TFX)) has held its Q3 earnings call. Read on for the main highlights of the call. Teleflex’s recent earnings call revealed a balanced ...

The NyokAssist device, from China, had few adverse outcomes by 30 days. More devices—and more trials—are on the way.

Teleflex expects adjusted gross margin for 2025 to be approximately 59% and adjusted operating margin to be approximately 24.5%. Adjusted EPS guidance for 2025 is narrowed to $14 to $14.20, from ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsLawrence Keusch - Vice President of Investor ...

Medical technology company Teleflex (NYSE:TFX) reported Q3 CY2025 results , with sales up 19.4% year on year to $913 million.

Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 28, 2025. Third quarter financial summary GAAP revenue of $913.0, up 19.4% ...

This news was covered by the Medical Dialogues Bureau, which was present at the TCT Conference 2025 held in San Francisco, ...

China’s heart pump device market is expanding rapidly, driven by robust clinical research and favorable regulatory reforms, with a projected CAGR of 21.7%. Japan invests heavily in healthcare ...

The rapid increase in the number of percutaneous coronary interventions being performed has led to a corresponding rise in the complexity of lesions attempted and the extent of patient comorbidities ...

"In short, it seems likely that the returned arterialized blood should be returned during diastole when the aortic valve is closed. This would probably offer less resistance to the ailing heart's ...